Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Bevacizumab for Hereditary Hemorrhagic Telangiectasia
NCT02157987Phase 2Completed
- Sponsor
- CHU Caen Normandie
- Start
- Dec 2014
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), sponsored by CHU Caen Normandie. Started Dec 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT02157987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157987.